$57.29
+4.55 (+8.63%)
Last updated: May 31, 2026 07:56
Fundamentals Overview
BioMarin Pharmaceutical Inc. is in the middle of its 52-week range with premium valuation, showing strong upward momentum today.
Valuation premium
Intrinsic value (DCF)
-80.6% downside vs price
Profitability
Risk (Beta)
0.23 — lower vol
Earnings & growth
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
Analyst grade: B+
Pressures (Sell):
DCF 80.6% downside vs price · Sentiment weakening (2 downgrades) · 3M vs S&P 500: -15.9%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: B+. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 11, Hold: 1, Market Perform: 1, Neutral: 5, Outperform: 5, Overweight: 6, Sector Perform: 1.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $11.13; current price is $57.29. That’s a -80.6% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 42.14 |
| DCF value (model) | $11.13 (-80.6% vs price) |
| PEG (TTM) | N/A |
| P/B (TTM) | 1.78 |
| P/S (TTM) | 3.42 |
| P/FCF (TTM) | 14.44 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 5.81 |
| Quick Ratio (TTM) | 4.2 |
| Cash Ratio (TTM) | 2.8 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 8.29% |
| Gross margin (TTM) | 75.93% |
| Operating margin (TTM) | 13.55% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for BMRN.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Canaccord Genuity | maintain | Buy | Buy | 2026-05-22 |
| B of A Securities | maintain | Buy | Buy | 2026-05-19 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2026-05-18 |
| Canaccord Genuity | maintain | Buy | Buy | 2026-05-07 |
| Bernstein | maintain | Outperform | Outperform | 2026-05-05 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2026-05-05 |
| RBC Capital | maintain | Sector Perform | Sector Perform | 2026-05-05 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-05-05 |
| Morgan Stanley | maintain | Overweight | Overweight | 2026-05-05 |
| B of A Securities | maintain | Buy | Buy | 2026-03-11 |
| Barclays | maintain | Overweight | Overweight | 2026-03-04 |
| Freedom Broker | maintain | Buy | Buy | 2026-03-02 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2026-03-02 |
| Canaccord Genuity | maintain | Buy | Buy | 2026-02-26 |
| Bernstein | maintain | Outperform | Outperform | 2026-02-25 |
| Guggenheim | maintain | Buy | Buy | 2026-02-25 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2026-02-25 |
| Oppenheimer | maintain | Outperform | Outperform | 2026-02-24 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-02-18 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-02-06 |
| Canaccord Genuity | upgrade | Hold | Buy | 2026-01-20 |
| Truist Securities | maintain | Buy | Buy | 2025-12-23 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2025-12-22 |
| Leerink Partners | downgrade | Outperform | Market Perform | 2025-12-03 |
| Stifel | downgrade | Buy | Hold | 2025-11-06 |
| Bernstein | maintain | Outperform | Outperform | 2025-11-03 |
| Freedom Broker | maintain | Buy | Buy | 2025-11-03 |
| Truist Securities | maintain | Buy | Buy | 2025-10-28 |
| Morgan Stanley | maintain | Overweight | Overweight | 2025-10-28 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-10-28 |